Fouquet, G.; Wartski, M.; Dechmi, A.; Willems, L.; Deau-Fischer, B.; Franchi, P.; Descroocq, J.; Deschamps, P.; Blanc-Autran, E.; Clerc, J.;
et al. Prognostic Value of FDG-PET/CT Parameters in Patients with Relapse/Refractory Multiple Myeloma before Anti-CD38 Based Therapy. Cancers 2021, 13, 4323.
https://doi.org/10.3390/cancers13174323
AMA Style
Fouquet G, Wartski M, Dechmi A, Willems L, Deau-Fischer B, Franchi P, Descroocq J, Deschamps P, Blanc-Autran E, Clerc J,
et al. Prognostic Value of FDG-PET/CT Parameters in Patients with Relapse/Refractory Multiple Myeloma before Anti-CD38 Based Therapy. Cancers. 2021; 13(17):4323.
https://doi.org/10.3390/cancers13174323
Chicago/Turabian Style
Fouquet, Guillemette, Myriam Wartski, Amina Dechmi, Lise Willems, Bénédicte Deau-Fischer, Patricia Franchi, Justine Descroocq, Paul Deschamps, Estelle Blanc-Autran, Jérôme Clerc,
and et al. 2021. "Prognostic Value of FDG-PET/CT Parameters in Patients with Relapse/Refractory Multiple Myeloma before Anti-CD38 Based Therapy" Cancers 13, no. 17: 4323.
https://doi.org/10.3390/cancers13174323
APA Style
Fouquet, G., Wartski, M., Dechmi, A., Willems, L., Deau-Fischer, B., Franchi, P., Descroocq, J., Deschamps, P., Blanc-Autran, E., Clerc, J., Bouscary, D., Barreau, S., Chapuis, N., Vignon, M., & Cottereau, A. -S.
(2021). Prognostic Value of FDG-PET/CT Parameters in Patients with Relapse/Refractory Multiple Myeloma before Anti-CD38 Based Therapy. Cancers, 13(17), 4323.
https://doi.org/10.3390/cancers13174323